Compare WIMI & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WIMI | HSCS |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 15.8M |
| IPO Year | 2019 | 2022 |
| Metric | WIMI | HSCS |
|---|---|---|
| Price | $0.78 | $3.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 169.1K | 136.1K |
| Earning Date | 04-24-2026 | 09-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,319.00 |
| Revenue This Year | N/A | $295.93 |
| Revenue Next Year | N/A | $18,321.05 |
| P/E Ratio | $1.24 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $1.63 |
| 52 Week High | $5.04 | $5.25 |
| Indicator | WIMI | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 18.37 | 54.67 |
| Support Level | N/A | $1.84 |
| Resistance Level | $1.43 | $4.35 |
| Average True Range (ATR) | 0.06 | 0.46 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 6.32 | 45.00 |
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.